FENC - Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
Story updates
11:34:13 AM UTC
SquawkNews
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Grade 4 Hearing Loss Was Observ…
11:34:39 AM UTC
SquawkNews
Fennec reported Phase 2 STS-J01 data for PEDMARK: ASHA-defined hearing loss in 24.0% vs a 56.4% historical benchmark (P=0.001), 84% Brock Grade 0, no Grade 3/4, and 95.8% objective responses in 23/24 evaluable patients. The company is pursuing registration and partnering in Japan.Material DetailsCo…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.